Personalized vaccine helped melanoma patients stay cancer-free longer, drugmakers say

Inside Moderna and Merck’s cancer vaccine triumph

Moderna and Merck's wild gambit on a cancer vaccine appears to have worked, despite big doubts, logistical challenges, and pandemic-era complications.

Personalized vaccine helped melanoma patients stay cancer-free longer, drugmakers say

An experimental vaccine kept melanoma from returning or spreading in people at high risk of the skin cancer recurring, drugmakers Moderna and Merck announced Wednesday.

Merck, Vidac Pharma, Moderna: New Cancer Treatments Send Stock Markets Soaring

Moderna: Cancer Breakthrough Triggers Share Price Surge Moderna has made a comeback with a quantum leap. Together with Merck, the biotech company reported positive Phase 3 results for the personalized mRNA cancer therapy Intismeran, when combined with the blockbuster Keytruda. In the study involving 1,137 patients with surgically treated high-risk melanoma, statistically significant and clinically relevant improvements were achieved compared to …